AlphaPepe is entering that conversation as its presale moves closer to selling out. The project has now raised more than $2 million, attracted over 10,300 holders, and reached a current presale price of $0.02158.

Launch preparations are underway, a second independent audit has been secured through Coinsult with a high score, and the team has confirmed that details of a fourth centralized exchange partnership will be announced soon.

AlphaPepe Presale Passes $2M as Final Window Tightens

AlphaPepe has now raised more than $2 million and built a community of over 10,300 holders before its exchange launch.

The current $ALPE presale price is $0.02158. That price remains fixed during the active stage, but it will not remain available once the remaining allocation closes.

This is where the urgency begins. Three CEX partnerships have already been announced, a fourth is coming soon, and the project is moving through launch preparations while buyers can still enter before open-market trading begins.

Once $ALPE reaches public price discovery, liquidity, exchange activity and market demand will determine the price.

Second Coinsult Audit Strengthens the Launch Setup

AlphaPepe has completed its second independent audit through Coinsult and received a high audit score.

The review adds another layer of external security assessment around the $ALPE token and its smart-contract infrastructure. It also gives prospective buyers more information to examine before participating in the presale.

AlphaSwap AI DEX Remains the Core Product Story

AlphaPepe is being developed as more than a standalone meme coin. The project already has AlphaSwap Early Access live, giving users an early look at its AI-powered decentralized exchange ecosystem supported by the $ALPE token.

AlphaSwap combines decentralized token trading with AI-assisted tools designed to help users assess market conditions, review token risks and make more informed decisions before executing a swap.

AlphaRouter is now being developed as the advanced routing layer behind the exchange. It will compare multiple liquidity paths before a transaction is completed, helping AlphaSwap identify more efficient routes and improve execution across available pools.

Cross-chain bridging is expected to follow after AlphaRouter goes live, allowing AlphaSwap to expand beyond single-chain trading and connect users with liquidity across additional blockchain networks.

Fourth CEX Partnership Announcement Coming Soon

AlphaPepe has already announced three centralized exchange partnerships, and the team has confirmed that a fourth partnership announcement is coming soon.

The exchange has not yet been named publicly. Buyers should rely only on AlphaPepe’s official website and verified social channels until the full announcement is released.

FINAL30 Gives Buyers 30% Extra Tokens

AlphaPepe has activated a limited-time offer while launch preparations are underway.

Buyers purchasing $100 or more can use promo code FINAL30 to receive 30% extra $ALPE tokens. The bonus is added to the standard token allocation available through an eligible purchase.

The FINAL30 campaign is available only for a limited period and may end as AlphaPepe moves closer to completing the presale.

Bitcoin Price Prediction and the Road to $200,000

Bitcoin price prediction forecasts continue to examine whether BTC could eventually reach $200,000 during another major market expansion.

The target remains speculative and would require sustained institutional demand, stronger global liquidity and enough new capital to move Bitcoin toward a market valuation of roughly $4 trillion.

Bitcoin still offers the strongest liquidity, recognition and market history in crypto. However, its size changes the percentage-upside equation.

AlphaPepe is operating at a different point in the cycle. Bitcoin already has a global chart, established liquidity and visible resistance levels. AlphaPepe remains in presale before public-market price discovery begins.

AlphaPepe Moves Toward Public Price Discovery

AlphaPepe has raised more than $2 million, passed 10,300 holders, completed its second Coinsult audit and confirmed that a fourth CEX partnership announcement is approaching.

The presale price remains $0.02158, but the window is closing as launch preparations move forward.

Eligible buyers purchasing $100 or more can use promo code FINAL30 to receive 30% extra tokens while the limited-time campaign remains active.

VISIT ALPHAPEPE OFFICIAL WEBSITE

FAQs

What is the Bitcoin price prediction for $200,000?
Bitcoin could potentially reach $200,000 if institutional demand, market liquidity and wider adoption continue to grow. The target remains speculative and would require Bitcoin to reach a market value of roughly $4 trillion.

Is the AlphaPepe presale closing soon?
Yes. AlphaPepe has raised more than $2 million, passed 10,300 holders and is moving through launch preparations. The current price is $0.02158, while purchases of $100 or more can receive 30% extra tokens using promo code FINAL30 for a limited time.

Contact:
Jack Duffy
contact@alphapepe.io

Disclaimer: This content is provided by AlphaPepe. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/30707cf6-b64d-4424-88ea-2dc2ba20ebd8

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lucid Group, Inc. (NASDAQ: LCID) between February 25, 2026 and April 13, 2026, inclusive (the “Class Period”), of the important July 28, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Lucid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (2) the foregoing was likely to, and did, have a material negative impact on Lucid’s business and financial results; (3) accordingly, the defendants had overstated the purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Erasca common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Erasca class action, go to https://rosenlegal.com/cases/erasca-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, Erasca, Inc., along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential “best-in-class” therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines’ competing drug candidate, RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Erasca class action, go to https://rosenlegal.com/cases/erasca-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

New York City, July 18, 2026 (GLOBE NEWSWIRE) —    

In 2026, we announced the launch of ColestZen to support a healthy cholesterol formula, Your Ultimate Partner in Managing Cholesterol and Metabolic Health. We are excited to present ColestZen, a premium capsule-based dietary supplement meticulously crafted to support healthy cholesterol levels and overall metabolic wellness. Designed specifically for adults over 35, ColestZen addresses the natural age-related metabolic slowdowns that can disrupt cholesterol balance and blood sugar regulation. The company confirmed that ColestZen for healthy cholesterol support is being introduced in the United States (USA), the United Kingdom (UK), Canada (CA), and Australia (AU) through its official online platform.

ColestZen combines a powerful blend of nine plant-based botanicals and nine essential micronutrients, delivering comprehensive cardiovascular support in one convenient formula. Key ingredients include bitter melon extract and cinnamon bark, known for their roles in blood sugar support and glucose metabolism, as well as licorice root extract and gymnema sylvestre, which help reduce sugar cravings and promote metabolic balance. This botanical synergy is enhanced by vital micronutrients such as L-taurine, an amino acid supporting heart function, alpha-lipoic acid, and essential minerals like magnesium and chromium, providing antioxidant protection and promoting healthy circulation.

Manufactured in a GMP-certified, FDA-registered facility in the USA, ColestZen ensures the highest quality and safety standards. This capsule dietary supplement is designed to complement your existing health routine and is not intended to replace prescribed cholesterol medication or prescription diabetes medication. If you are currently taking such medications, consulting your healthcare provider before use is essential.

With a simple recommended dosage of two capsules daily, ColestZen begins absorbing immediately to support your body’s natural cholesterol metabolism and balanced blood sugar. Backed by a 60-day money-back guarantee, ColestZen offers a trusted, risk-free option for those seeking natural, effective cardiovascular and metabolic support. Embrace ColestZen today and take a proactive step toward long-term heart health and metabolic wellness.ColestZen: Your Partner in Managing Cholesterol and Metabolic Health

ColestZen is a thoughtfully formulated dietary supplement designed to support healthy cholesterol levels and overall metabolic health for adults seeking natural, daily wellness solutions. As many individuals over 35 experience age-related metabolic slowdowns that can affect cholesterol balance and blood sugar regulation, ColestZen offers a comprehensive approach to address these concerns without relying solely on prescription medications. 

Official Website: https://shop-colestzen.org/

This capsule-based supplement combines a unique blend of nine plant-based botanicals and nine essential micronutrients to promote cardiovascular wellness, healthy circulation, and balanced glucose metabolism. Key botanical ingredients such as bitter melon extract, cinnamon bark, licorice root extract, and gymnema sylvestre work synergistically to support blood sugar balance and metabolic function. Complementing these are micronutrients like L-taurine, alpha lipoic acid, vitamins C and E, magnesium, and chromium, which provide antioxidant protection and help maintain vascular health.

ColestZen is manufactured in a GMP-certified, FDA-registered facility in the USA, adhering to strict manufacturing process standards to ensure quality and consistency. It is designed as a convenient addition to an existing healthy cholesterol routine and is not a drug or a substitute for prescribed medications. Individuals taking blood pressure medication or prescription glucose-lowering drugs should consult their healthcare provider before use.

With a recommended dosage of two capsules daily and a 60-day money-back guarantee, ColestZen offers a risk-conscious option for those looking to support their cardiovascular and metabolic health naturally. Its comprehensive formula aims to nourish multiple pathways involved in heart health, making it a valuable partner in your journey toward maintaining healthy cholesterol levels and metabolic balance.

ColestZen officially introduces its first healthy cholesterol support supplement, marking a significant milestone in successful product development.

ColestZen, an innovative capsule dietary supplement, is designed to support healthy cholesterol levels, balanced blood sugar, and overall cardiovascular and metabolic health. Formulated with a unique blend of nine plant-based botanicals and nine essential micronutrients, ColestZen aims to provide comprehensive support for individuals seeking to maintain their existing healthy cholesterol routine.

The carefully crafted formula includes ingredients such as bitter melon extract, cinnamon bark, licorice root extract, gymnema sylvestre, mulberry fruit powder, cayenne pepper extract, and juniper berry powder, combined with essential minerals and amino acids like L-taurine and alpha lipoic acid. These components work synergistically to promote healthy circulation, support blood sugar balance, and provide antioxidant protection, contributing to metabolic balance and cardiovascular wellness.

ColestZen is manufactured in an FDA-registered, GMP-certified facility in the USA, ensuring high manufacturing process standards and product safety. The brand emphasizes that ColestZen is not a drug but a capsule-based dietary supplement intended to complement, not replace, prescribed cholesterol medication or blood pressure medication.

Consumers can conveniently incorporate ColestZen into their daily health regimen by taking two capsules daily, ideally alongside a healthy lifestyle that includes proper nutrition and regular exercise. The brand offers a 60-day money-back guarantee, reflecting confidence in the product’s quality and customer satisfaction.

ColestZen also provides dedicated customer support and a transparent shipping policy, although international shipping details should be verified directly with the brand. This comprehensive approach positions ColestZen as a promising option for adults over 35 looking to support healthy cholesterol levels and overall metabolic health naturally.

ColestZen Announces a Daily Cholesterol Support Formula for Adults 

Many adults, especially those over 35, notice their cholesterol numbers creeping up despite reasonable diet and exercise habits. You might also experience symptoms like low energy or suspect circulatory issues. ColestZen is marketed as a natural supplement designed to provide daily support for cholesterol balance, blood sugar regulation, and overall cardiovascular wellness without the need for prescription-strength interventions.

The brand’s marketing focuses on a concept termed a “hidden metabolic slowdown,” which they suggest may contribute to rising LDL cholesterol levels after age 35, independent of dietary factors. This narrative is presented on the product’s sales page as a potential explanation for cholesterol challenges but is not a medical diagnosis nor independently validated in this review. What is verifiable is that ColestZen is a proprietary-blend dietary supplement in capsule form, intended to be taken twice daily. It is sold directly through the brand’s official website in one-time payment bundles comprising two, three, or six bottles.

It is important to understand that ColestZen is not suitable for everyone. It is not intended as a replacement for prescribed cholesterol medications. Individuals with diagnosed cardiovascular conditions should consult their healthcare provider before adding any new supplement to their regimen. Additionally, ColestZen is not recommended for pregnant or nursing women, nor for individuals under 18 years of age. The brand’s FAQ explicitly advises showing the product label to a healthcare professional before starting. This caution is particularly relevant because some botanicals in the formula, notably licorice root and cinnamon, have known interactions with blood pressure and blood sugar medications. The specific effects at the undisclosed doses used in ColestZen are unknown and are discussed further below.

 Researching Ingredients, Safety

Maintaining a healthy lifestyle is the most effective approach to preventing and manage high cholesterol. However, for some individuals, diet and exercise alone may not be sufficient to keep cholesterol levels within a healthy range. In such cases, alongside lifestyle modifications, some people choose to incorporate dietary supplements like ColestZen into their daily routine. Others may require prescription cholesterol medications as recommended by their healthcare professional to:

• Lower low-density lipoprotein (LDL) cholesterol, often referred to as the “bad” cholesterol, which contributes to plaque buildup in arteries and raises the risk of heart disease.
• Reduce triglycerides, a type of fat found in the blood that, when elevated, also increases cardiovascular risk.
• Increase high-density lipoprotein (HDL) cholesterol, the “good” cholesterol that helps remove excess cholesterol from the bloodstream and protects against heart disease.

Healthcare providers may prescribe a single medication or a combination of cholesterol-lowering drugs tailored to individual needs. If you are exploring supplement options, you may have encountered ColestZen. 

A Science-Inspired Approach to support healthy cholesterol levels and balanced blood sugar

ColestZen offers a science-inspired approach designed to support healthy cholesterol levels and balanced blood sugar through a carefully crafted blend of botanical extracts and essential nutrients. This capsule dietary supplement combines nine plant-based botanicals with nine essential micronutrients, targeting multiple pathways involved in cardiovascular and metabolic health.

Key botanical ingredients include bitter melon extract and gymnema sylvestre, both known for their roles in supporting blood sugar balance and reducing sugar cravings. Cinnamon bark and banaba leaf extract promote healthy glucose metabolism, while mulberry fruit powder and licorice root extract provide antioxidant protection and contribute to metabolic balance. The formulation also contains amino acids such as L-taurine and alpha lipoic acid, which support heart function and offer antioxidant benefits, further promoting cardiovascular health. Additionally, cayenne pepper extract and juniper berry powder are included to encourage healthy circulation and support the body’s natural detoxification processes.

This comprehensive capsule dietary supplement is designed to assist the body’s natural ability to maintain healthy cholesterol levels already within the normal range and support balanced blood sugar, both essential for long-term metabolic and cardiovascular wellness.

ColestZen is manufactured in a GMP-certified, FDA-registered facility, ensuring adherence to high manufacturing process standards for quality and safety. The brand states that the finished ColestZen formula specifically begins absorbing immediately after intake, with a recommended dosage of two capsules daily. When paired with a healthy lifestyle that includes proper nutrition and regular exercise, ColestZen provides a convenient and holistic way to support heart health and metabolic balance.

It is important to note that ColestZen is not a drug and should not be used as a replacement for prescribed cholesterol medication or blood pressure medication. Instead, it serves as a complementary supplement designed to nourish essential mineral and nutrient pathways in the body, offering a natural and balanced approach to managing cholesterol and blood sugar levels.

ColestZen contains 18 ingredients, divided into two categories: 9 botanicals and 9 micronutrients.

The botanical ingredients and their purported roles according to the brand are:

• Bitter Melon Extract (fruit): Traditionally used in South and Southeast Asian cuisine and herbal medicine, positioned for supporting healthy blood sugar metabolism.
• Cinnamon (bark): A common culinary spice, framed as promoting healthy glucose metabolism and supporting cholesterol balance.
• Licorice Extract (root): Traditionally used for digestive health and metabolic balance. Notably, licorice root contains glycyrrhizin, which can affect blood pressure and potassium levels.
• Gymnema Sylvestre (leaf powder): Known as the “sugar destroyer” in Ayurvedic medicine, marketed for reducing sugar cravings and supporting blood sugar regulation.
• Banaba Extract (leaf): Contains corosolic acid, believed to support glucose metabolism and insulin activity.
• Mulberry Fruit Powder (fresh fruit): Contains antioxidants and compounds that may support carbohydrate metabolism and balanced blood sugar.
• Yarrow Herb Powder (whole herb): Traditionally used to promote healthy circulation and vascular function.
• Cayenne Pepper Extract: Contains capsaicin, which may promote blood flow and metabolic rate.
• Juniper Berry Powder: Associated with detoxification and fluid balance support.

The micronutrient layer includes:

• L-Taurine: An amino acid supporting heart function, blood flow, and fat metabolism.
• Alpha Lipoic Acid: An antioxidant compound that supports insulin sensitivity and blood sugar regulation.
• Vitamin C: A well-known antioxidant that supports vessel wall integrity and arterial elasticity.
• Vitamin E: Protects against oxidized LDL cholesterol and supports healthy blood flow.
• Biotin: A B-vitamin involved in fat metabolism.
• Magnesium: Supports muscle and nerve function as well as blood pressure regulation.
• Zinc: Supports liver health and arterial wall function.
• Manganese: A cofactor for antioxidant enzymes.
• Chromium: Supports blood sugar regulation and metabolic balance.

Several micronutrients, including vitamins C and E, magnesium, and chromium, have well-established research supporting their roles in cardiovascular and metabolic health. However, this general research does not confirm the effects of ColestZen’s specific formula or undisclosed ingredient dosages.

The company states that ColestZen is designed to complement wellness-focused routines by supporting several areas that many people consider important when working toward healthy lifestyle goals, including maintaining healthy cholesterol levels, promoting balanced blood sugar, supporting cardiovascular function, and enhancing metabolic balance

• Supports healthy cholesterol levels already within the normal range
• Promotes balanced blood sugar and glucose metabolism
• Contains a blend of 18 ingredients, including botanicals and essential micronutrients
• Encourages healthy circulation and cardiovascular function
• Provides antioxidant protection to support metabolic wellness
• Manufactured in an FDA-registered, GMP-certified facility for quality assurance
• Easy daily use: two capsules with water, ideally in the morning
• Complements an existing healthy cholesterol routine and lifestyle habits

Meeting Consumer Demand for Healthy Cholesterol Support Solutions

Meeting consumer demand for healthy cholesterol solutions requires a comprehensive approach that combines education, quality ingredients, and transparent communication. As awareness about cardiovascular and metabolic health grows, consumers increasingly seek products that not only support healthy cholesterol levels but also promote balanced blood sugar and blood pressure. To address this demand, manufacturers must develop capsule-based dietary supplements that integrate a blend of botanicals and essential micronutrients known for their beneficial effects on heart health and metabolic balance.

A product like ColestZen specifically exemplifies this trend by offering a finished formula designed to support healthy cholesterol levels alongside blood sugar support. Incorporating ingredients such as alpha lipoic acid, mulberry fruit powder, juniper berry powder, and cayenne pepper extract, the supplement targets multiple pathways to enhance cardiovascular and metabolic wellness. The inclusion of amino acids like L-taurine further supports heart function and energy metabolism. However, meeting consumer expectations goes beyond formulation. Brands must ensure manufacturing process standards, including GMP certification and production in FDA-registered facilities, to guarantee safety and efficacy.

Transparent brand materials, including published supplement facts panels, foster trust by allowing consumers to make informed decisions. Moreover, clear communication about potential interactions between supplement ingredients and prescribed medication—such as prescription glucose-lowering medication or blood pressure medication—is vital for user safety. Consumers taking prescription diabetes medication or prescribed medication for cholesterol should consult healthcare professionals before use. Providing accessible colestzen customer support and a fair refund policy, such as a 60-day money-back guarantee, further strengthens consumer confidence.

Ultimately, the key to meeting consumer demand lies in delivering a reliable, well-researched, and safe supplement like ColestZen that complements an existing healthy cholesterol routine. By focusing on metabolic and cardiovascular health holistically, brands can offer effective solutions that resonate with health-conscious individuals seeking natural, supportive options for long-term wellness.

Focus on Wellness Education

ColestZen is more than just a dietary supplement—it’s a comprehensive wellness partner dedicated to helping you understand and support your heart and metabolic health in a holistic way. The brand believes that maintaining healthy cholesterol levels and achieving blood sugar balance isn’t merely about taking pills; it’s about empowering yourself with knowledge on how nutrition, lifestyle choices, and responsible supplement use all integrate to promote cardiovascular and metabolic well-being. To that end, ColestZen offers a wealth of educational resources that explain the fundamentals of heart health, the critical role of metabolic balance, and practical guidance on how to seamlessly incorporate natural support into your daily routine.

The brand emphasizes that true cardiovascular health arises from a multifaceted approach encompassing good nutrition, regular physical activity, effective stress management, and vigilant monitoring of overall health markers. By helping consumers understand how these elements interconnect, ColestZen encourages the development of sustainable habits that support cardiovascular and metabolic wellness over the long term. Importantly, the brand stresses the necessity of using supplements responsibly—particularly for individuals already taking prescribed cholesterol medication, prescription diabetes medication, or blood pressure drugs. ColestZen recommends consulting with healthcare providers before adding its capsule-based dietary supplement to your existing regimen to ensure safety and avoid potential interactions.

Adapting to Today’s Wellness Trends

ColestZen has been thoughtfully formulated to align with the rising consumer demand for natural, effective, and convenient health products that fit modern lifestyles. Its finished colestzen formula specifically reflects a contemporary approach to prevention and maintenance, offering well-rounded cardiovascular and metabolic support in a convenient capsule form designed to integrate effortlessly into busy daily schedules.

Several key wellness trends shape the development and positioning of ColestZen:

Personalized Wellness

Recognizing that every individual’s health journey is unique, ColestZen is designed to support a broad spectrum of wellness goals. Whether your focus is on dietary improvements, increasing physical activity, or managing stress, this finished colestzen formula helps maintain healthy cholesterol levels, supports blood sugar balance, and promotes healthy circulation without disrupting your existing health plan or prescribed medications. This adaptability makes ColestZen a versatile choice for adults over 35 seeking natural support tailored to their personal health needs.

Simple Daily Routine

In today’s fast-paced world, maintaining consistent health habits can be challenging. ColestZen’s twice-daily capsule regimen is designed for simplicity and ease of use, with ingredients that begin absorbing immediately to provide timely metabolic and cardiovascular support. This capsule dietary supplement offers a hassle-free way to incorporate essential nutrients into your day, ensuring even the busiest individuals can stay on track with their heart and metabolic health goals.

A Whole-Body Approach

Heart health is intricately connected with overall metabolism, antioxidant status, and circulatory function. ColestZen’s ingredient blend combines nine botanicals—such as mulberry fruit powder, juniper berry powder, cayenne pepper extract, and licorice root extract—with nine essential micronutrients including alpha lipoic acid and L-taurine. These components work synergistically to support the cardiovascular system, promote blood sugar balance, and enhance healthy circulation, illustrating the brand’s commitment to a holistic wellness philosophy that addresses multiple pathways involved in heart and metabolic health.

Honesty and Quality

Building trust with consumers is a cornerstone of ColestZen’s brand ethos. The supplement is manufactured in an FDA-registered, GMP-certified facility, ensuring adherence to stringent safety and manufacturing process standards. The brand is transparent about its proprietary ingredient blend, refund policies, and customer support channels, providing detailed information that helps users feel confident and well-informed about their purchase. This openness extends to acknowledging the supplement is not a drug and is not intended to replace prescribed cholesterol medication or other prescribed therapies.

Supporting Active, Healthy Lives

ColestZen encourages users to view supplements as one component within a comprehensive health strategy that includes regular exercise, balanced nutrition, proper hydration, and sufficient rest. The brand underscores that maintaining healthy cholesterol levels and metabolic function requires steady, sustainable lifestyle habits supported by targeted nutrition. By aiding in energy management, curbing sugar cravings, and supporting healthy blood pressure, ColestZen contributes to overall cardiovascular and metabolic wellness, helping users sustain an active and vibrant lifestyle.

Built Around You

The development of ColestZen was informed by consumer research and feedback from adults over 35 who seek natural, safe, and effective ways to support heart and metabolic health despite demanding schedules. The brand’s bundle structure offers flexible purchasing options, including multi-bottle packages with bonus guides that provide additional education on artery health and energy management. This user-centric approach ensures that ColestZen delivers both value and support beyond the supplement itself.

Commitment to High Standards

Produced in a facility that meets FDA registration and GMP certification requirements, ColestZen adheres to high manufacturing process standards that prioritize product purity, consistency, and safety. The brand is upfront about potential interactions, particularly for those taking prescription diabetes medication or blood pressure medication, and it offers a clear 60-day money-back guarantee to demonstrate confidence in customer satisfaction. This commitment reflects ColestZen’s dedication to responsible production and consumer trust.

Looking Forward

ColestZen plans to expand its educational offerings, providing ongoing tips and insights on heart health, blood sugar management, natural blood pressure support, and the role of key nutrients like alpha-lipoic acid and amino acids in cardiovascular wellness. The brand’s goal is to empower consumers to make informed health choices and embrace natural options that complement prescribed treatments, fostering confidence and support throughout their wellness journey.

Industry Insight

Health professionals and metabolic and cardiovascular researchers agree that heart and metabolic health depend on a complex interplay of factors including nutrition, physical activity, stress management, and adherence to medical advice. While supplements like ColestZen can offer supportive benefits, they are not substitutes for prescribed medication such as prescribed cholesterol medication or prescription glucose lowering medication. ColestZen advocates for its capsule-based dietary supplement to be used as part of a comprehensive health plan under the guidance of healthcare professionals, emphasizing the importance of awareness regarding potential interactions with prescribed medication.

Availablity

ColestZen is exclusively available through the official ColestZen website, which provides comprehensive product information, current colestzen pricing, bundle options, and shipping details. The site also includes a dedicated shipping policy page and customer support contacts for inquiries, including questions about colestzen shipping internationally. Before starting ColestZen, especially if you are taking prescribed medication or managing health conditions, it is advisable to follow usage guidelines carefully and consult your healthcare provider to ensure safety and compatibility with your existing regimen.

In summary,

 ColestZen is a wellness-focused brand offering a finished ColestZen formula designed to support healthy cholesterol levels, balanced blood sugar, and overall cardiovascular wellness. With its emphasis on education, quality manufacturing, transparency, and user empowerment, ColestZen provides a natural, safe, and effective option to complement your long-term health goals and existing healthy cholesterol routine. This capsule-based dietary supplement, containing nine plant-based botanicals and nine essential micronutrients, supports cardiovascular and metabolic health by promoting healthy circulation, blood sugar balance, and antioxidant protection. By integrating ColestZen into a broader lifestyle approach that includes proper nutrition, exercise, and medical guidance, users can take proactive steps toward maintaining their heart and metabolic health for years to come.

References: https://finance.yahoo.com/healthcare/articles/burntide-official-announces-2026-across-114600901.html

                    https://finance.yahoo.com/healthcare/articles/nativepath-2026-launch-effective-native-143600522.html

Contact Information

• Company: ColestZen
• Website: https://shop-colestzen.org/
• Email: support@trycolestzen.com
• Phone: (305) 457-6427
• Support Hours: Monday–Friday, 9:00 AM – 6:00 PM (Eastern Time)

SOUTHLAKE, Texas, July 17, 2026 (GLOBE NEWSWIRE) — American Fusion Inc. (OTC: AMFN) (“American Fusion” or the “Company”), developer of the proprietary Texatron^™ Fusion Engine^™, announced that it has received a Certificate for Industrial Radiation Machines from the Texas Department of State Health Services (“DSHS”), representing a significant regulatory and operational milestone as the Company continues executing its engineering, testing, and validation program.

Issued on July 17, 2026, the Certificate of Registration authorizes American Fusion to conduct research and development activities involving its registered Texatron^™ research systems at the Company’s approved testing location at Texas Tech University in Lubbock, Texas, subject to the conditions of the registration and applicable Texas radiation control regulations. The registration identifies Dr. John E. Brandenburg as the Company’s Radiation Safety Officer and remains effective through February 28, 2034. The Certificate may also be independently verified by clicking here to access the Texas Department of State Health Services database and entering Registration No. R54726 in the License Number field.

The registration authorizes the Company to receive, possess, acquire, transfer, and use registered industrial radiation machines for research and development purposes in accordance with the Texas Radiation Control Act, applicable provisions of 25 Texas Administrative Code Chapter 289, the Company’s submitted operating procedures, shielding and safety information, and radiation safety program. The registration expressly limits the authorized activities to research and development and prohibits deliberate radiation exposure of humans. This Certificate represents the principal regulatory authorization supporting the Company’s planned research, engineering, prototype development, testing, validation, and future production of Texatron^™ Fusion Engine^™ systems in accordance with applicable Texas regulations. No other known material permits, licenses, certificates, or regulatory approvals are required to conduct the planned testing of the Company’s 5 MW Texatron^™ Fusion Engine^™ at Texas Tech University.

A Significant Regulatory and Operational Milestone

American Fusion believes receipt of the registration represents a significant regulatory and operational milestone supporting the Company’s continued engineering, prototype testing, and validation activities. The registration establishes the regulatory framework under which the Company intends to conduct research involving its Texatron^™ Fusion Engine^™ platform in accordance with applicable Texas radiation control requirements.

Brent Nelson, Executive Chairman of American Fusion, commented, “Receiving this Certificate of Registration reflects years of engineering preparation, radiation safety planning, and regulatory coordination. We appreciate the professionalism of the Texas Department of State Health Services throughout the review process. This registration represents a significant regulatory and operational milestone as we continue advancing the Texatron development program and preparing for the next phase of engineering and prototype testing.”

Twelve Texatron^™ Research Systems Authorized

The registration authorizes research and development activities involving the Company’s current family of Texatron^™ research systems, including:

• Texatron^™ 500 kW Fusion Engine^™

• Texatron^™ 1 MW Fusion Engine^™

• Texatron™ 5 MW Fusion Engine™

• Texatron^™ 10 MW Fusion Engine^™

• Texatron^™ 20 MW Fusion Engine^™

• Texatron^™ 30 MW Fusion Engine^™

• Texatron^™ 50 MW Fusion Engine^™

• Texatron^™ 75 MW Fusion Engine^™

• Texatron^™ 100 MW Fusion Engine^™

• Texatron^™ 250 MW Fusion Engine^™

• Texatron^™ 500 MW Fusion Engine^™

• Texatron^™ 1 GW Fusion Engine^™

The registration also identifies the Company’s approved research location, designated Radiation Safety Officer, applicable operating procedures, radiation safety program, shielding information, and the authorized serial number ranges associated with each registered research system.

Advancing the Development Roadmap

The Certificate of Registration establishes the regulatory framework under which American Fusion intends to conduct research and development activities involving its registered Texatron^™ Fusion Engine^™ systems at its approved Texas Tech research location. The registration provides the pathway for continued engineering, prototype testing, calibration, diagnostic evaluation, and technical validation activities in accordance with applicable Texas radiation control regulations.

Michael G. Smith, Chief Legal Officer of American Fusion, stated, “This achievement reflects an extraordinary collaborative effort across engineering, legal, technical, and regulatory disciplines. It demonstrates the Company’s commitment to disciplined engineering, regulatory compliance, and responsible execution of its development program. Obtaining the registration represents a significant regulatory and operational milestone that supports the Company’s continued engineering, testing, and validation efforts.”

Fabrice David, Independent Director of American Fusion, commented, “Today’s announcement reflects another important step in the Company’s continued development. The combination of engineering innovation, regulatory discipline, and scientific rigor continues to position American Fusion for the next phase of its research and development program. I congratulate the entire team on reaching this significant milestone.”

American Fusion intends to continue advancing its development program through engineering refinement, prototype testing, calibration, diagnostic evaluation, and additional technical validation activities. The Company expects to provide future updates as significant engineering, operational, and regulatory milestones are achieved.

About American Fusion Inc.

American Fusion Inc. (OTC: AMFN) is an advanced energy platform company focused on the development and commercialization of next-generation fusion energy technologies. The Company is advancing the Texatron^™ Fusion Engine^™ aneutronic fusion platform, designed for modular, infrastructure-grade deployment across industrial, commercial, defense and grid-constrained applications.

The Company’s development strategy emphasizes system-level engineering, disciplined intellectual property protection, and scalable architectures intended to support long-term commercial operation, while maintaining a focus on capital discipline and transparent corporate governance.

For more information about American Fusion and its Texatron^™ platform, please visit: americanfusionenergy.com

For an overview of American Fusion, please click here: American Fusion Overview

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Company’s plans, objectives, expectations, and intentions relating to technology development and commercialization, system integration and testing activities, patent filings, regulatory initiatives, financing activities, SEC registration and reporting matters, exchange uplisting initiatives, future business operations, and related matters.

Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks related to technology development, testing outcomes, intellectual property protection, regulatory approvals, financing availability, litigation matters, SEC reporting timelines, exchange requirements, market conditions, and other factors beyond the Company’s control.

This press release is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company undertakes no obligation to update forward-looking statements except as required by law.

Corporate Communications

info@americanfusionenergy.com
americanfusionenergy.com

On June 7, 2026, Bibb County Sheriff’s Office deputies were called to a Circle K gas station on Mercer University Drive in Macon, Georgia, after reports of a shooting. A woman was found in the roadway with a gunshot wound to her lower leg and was transported to a medical facility in critical condition.

The suspect departed the scene in a vehicle. Flock cameras registered the vehicle traveling south on Harrison Road. Deputies located and pursued it, ultimately using a PIT maneuver to bring it to a stop. The suspect refused to exit and discharged a firearm toward deputies before he was taken into custody and transported for medical treatment.

The woman shot at the gas station died from her wounds on June 12, 2026. With her death, the suspect’s primary charge was elevated to murder. He also faces charges of aggravated assault on law enforcement officers and felony fleeing and eluding.

Cases like this reflect how Flock’s technology is designed to work: giving investigators real leads quickly while upholding rigorous standards for privacy and responsible use.

###

About Flock

Flock is a public safety technology company that builds connected camera, audio, and investigative systems to help communities respond to and investigate safety incidents using objective evidence.

Flock technology combines video, gunshot detection, and investigative software to help law enforcement, schools, and businesses locate vehicles, understand incidents, and collaborate across jurisdictions while maintaining clear privacy safeguards, local control, and responsible data use.

Learn how Flock technology is used, how the system works, and the safeguards that govern data access and privacy at flocksafety.com and our Trust & Transparency page.

CONTACT: Flock media@flocksafety.com 

AI, Private Credit, and the Future of Cash Flow Lending

New York, NY , July 16, 2026 (GLOBE NEWSWIRE) — Executive Summary

Artificial intelligence is rapidly becoming one of the defining investment themes of our generation. Investors have spent considerable time discussing the companies building AI, the infrastructure required to support it, and the extraordinary productivity gains it may create.

Far less attention has been paid to a different question:

How might artificial intelligence reshape private credit portfolios?

For more than a decade, private credit has delivered attractive returns by financing businesses across a broad range of industries. Yet many of today’s institutional private credit portfolios contain significant exposure to software companies, technology-enabled services businesses, professional services firms, and private equity-backed enterprises whose cash flows are ultimately tied to the knowledge economy.

As AI continues to evolve, investors may benefit from examining not only the yield generated by their private credit investments but also the economic foundations supporting those yields.

At Supervest, we believe this discussion deserves greater attention.

Supervest

The Hidden Concentration Within Private Credit

Private credit has grown into a multi-trillion-dollar asset class over the past decade. Much of that growth has occurred alongside the expansion of private equity, enterprise software, technology-enabled services, and professional services businesses.

Many private credit portfolios today contain meaningful exposure to:

• Software companies
• Technology-enabled service providers
• Information services firms
• Consulting businesses
• Business process outsourcing providers
• Professional services companies
• Private equity-backed leveraged buyouts

Historically, these have been attractive borrowers. They often possess recurring revenue, asset-light business models, attractive margins, and predictable growth profiles.

However, investors should consider a simple question:

How much of the cash flow supporting these businesses ultimately depends upon the continued scarcity of human intelligence?

For decades, the answer was straightforward. Human expertise was scarce, valuable, and difficult to replicate.

A consulting firm’s value was built upon the specialized knowledge of its employees. A software company relied on teams of developers to create and maintain products. Professional service organizations depended upon highly skilled workers whose expertise could not easily be replaced.

Artificial intelligence may begin to alter that equation.

Tasks that once required large teams of analysts, developers, researchers, or administrators can increasingly be performed with fewer people and greater efficiency. While AI is unlikely to eliminate these industries, it may change the economics that support them. Investors should consider how businesses whose value is tied primarily to human knowledge and information processing may evolve in a world where intelligence itself becomes more abundant.

When Recurring Revenue Isn’t Necessarily Permanent

Many private credit investments are underwritten using assumptions regarding future earnings, customer retention, and recurring revenue streams.

Historically, those assumptions have generally proven reliable.

The challenge is that AI may create uncertainty around business models that previously appeared highly predictable.

If software development costs continue to decline, if enterprise customers begin replacing certain software subscriptions with internally developed AI-enabled tools, or if portions of professional services become increasingly automated, some businesses may face pressures that were not contemplated when many loans were originally underwritten.

The question is not whether these companies survive.

The question is whether future cash flows prove as durable as originally expected in order to service the outstanding debt obligations.

Investors often view private credit as a diversification away from public technology markets. Yet many private credit portfolios remain heavily dependent upon the same underlying drivers:

• Enterprise software spending
• Knowledge-worker employment
• Professional services demand
• Technology budgets
• Corporate productivity growth

As artificial intelligence reshapes these markets, investors may benefit from considering whether their credit exposure is truly diversified.

What Public Markets May Already Be Signaling

While much of the discussion surrounding artificial intelligence remains theoretical, public equity markets may already be providing clues regarding how investors are evaluating certain business models.

Over the past several months, many Software-as-a-Service (SaaS) companies have experienced significant valuation compression despite continued growth in the broader technology sector. Investors have also begun questioning the durability of software pricing, customer retention, and long-term competitive advantages in an increasingly AI-enabled environment.

The phenomenon has become so widespread that market participants have coined terms such as “SaaS Apocalypse” to describe the repricing that has occurred across portions of the software sector.

Whether that characterization ultimately proves accurate is less important than the underlying message.

Public market investors appear increasingly willing to challenge assumptions that were once considered almost universally accepted:

• That recurring revenue automatically equates to durable revenue
• That software businesses possess unlimited pricing power
• That customer retention rates will remain unchanged indefinitely
• That technology-enabled businesses are insulated from disruption themselves

For private credit investors, these developments warrant attention.

Many private credit portfolios contain borrowers whose cash flows are directly or indirectly tied to the same economic forces currently being reassessed in public markets. While private valuations often move more slowly than public valuations, history suggests that public markets frequently identify changing business fundamentals before they become evident elsewhere.

The question is not whether software companies remain attractive businesses. Many undoubtedly will.

The question is whether investors are being adequately compensated for risks that may not have existed when many private credit investments were originally underwritten.

Understanding the Underlying Cash Flow

When evaluating private credit investments, investors often focus on yield, leverage, duration, and credit quality.

Equally important, however, is understanding the source of the borrower’s cash flow.

Many private credit investments are ultimately supported by businesses whose revenues depend upon enterprise technology spending, professional services demand, and knowledge-worker productivity.

These businesses may continue to perform well for years to come. However, as artificial intelligence evolves, investors should recognize that some of the assumptions supporting those cash flows may be changing.

The objective is not to predict disruption. Rather, it is to understand where potential disruption may occur and how concentrated a portfolio may be in those areas.

In our view, the most resilient portfolios are often those that combine multiple sources of economic exposure rather than relying heavily on a single segment of the economy.

A Different Perspective From Main Street

At Supervest, we spend our time evaluating and financing small and medium-sized businesses operating across the United States.

Since inception, the Supervest ecosystem has facilitated participation in more than 50,000 funding transactions representing over $2 billion in capital provided to Main Street businesses. This experience provides a unique perspective on how small businesses are evolving in real time.

What we find notable is that many of the businesses we continue to find attractive operate in sectors that appear substantially less exposed to direct AI displacement.

These include:

• Medical practices
• Dental groups
• Specialty contractors
• Home service businesses
• Restaurants
• Automotive services
• Skilled trades
• Local service providers

These businesses may adopt AI.

In fact, many already are.

But their underlying value proposition remains rooted in physical execution and real-world commerce.

Artificial intelligence may help an HVAC company schedule jobs more efficiently.

It cannot install the system.

AI may help a dental practice automate administrative tasks.

It cannot perform the procedure.

Technology may improve productivity, but the underlying demand remains tied to activities occurring in the physical economy.

What We Are Seeing Within the Supervest Ecosystem

One advantage of operating within the small-business finance market is the ability to observe economic activity at the ground level.

Through our platform and affiliated funding relationships, we have participated in financing tens of thousands of small and medium-sized businesses across a broad range of industries.

While economic conditions and individual business performance naturally fluctuate, several observations have become increasingly apparent.

Many of the sectors we continue to find most attractive are those rooted in the physical economy.

Medical practices continue to provide healthcare services.

Specialty contractors continue to address labor shortages more often than demand shortages.

Home service providers continue to benefit from aging housing stock and ongoing maintenance needs.

Restaurants continue to serve local communities.

These businesses are not immune from economic cycles, nor are they immune from technological change. However, their revenue streams remain tied to activities that require physical execution, local relationships, and direct customer interaction.

Equally important, we are beginning to observe many of these businesses adopting artificial intelligence as a productivity tool rather than experiencing it as a competitive threat.

Contractors are utilizing AI to generate estimates and proposals.

Medical practices are automating administrative functions.

Local service providers are improving scheduling, marketing, and customer communication.

In many cases, AI appears to be enhancing operational efficiency without fundamentally disrupting the underlying business model, allowing businesses to improve profitability while continuing to serve the same core demand

This dynamic may prove important in the years ahead.

Duration Matters

Periods of technological change create challenges for long-term forecasting.

Many traditional private credit investments are underwritten against assumptions extending several years into the future.

The further investors attempt to forecast, the greater the uncertainty surrounding technological disruption.

One characteristic we continue to find attractive about revenue-based financing is its relatively short duration.

Capital is recycled more frequently.

Performance can be evaluated continuously.

Portfolio allocations can be adjusted more quickly as conditions evolve.

In a rapidly changing AI environment, flexibility may become increasingly valuable.

Following the Cash Flow

Ultimately, every credit investment comes down to a single question:

Where does the cash flow come from?

As artificial intelligence continues to reshape industries, investors may increasingly focus not only on expected returns, but also on the source and durability of those returns.

Some cash flows may become more dependent upon the future value of human knowledge work.

Others may remain tied to businesses repairing homes, serving customers, treating patients, and supporting local economies.

Neither approach is inherently right or wrong.

But understanding the distinction may become increasingly important.

Conclusion

The purpose of this discussion is not to suggest that artificial intelligence will destroy entire industries or invalidate traditional private credit.

Rather, it is to encourage investors to think more deeply about where their credit exposure resides.

Private credit has historically been viewed as a diversification away from public equity markets. Yet many private credit portfolios remain concentrated in businesses whose fortunes are tied to the same knowledge economy, enterprise technology spending, and white-collar employment trends that artificial intelligence is now beginning to reshape.

At the same time, a significant portion of the U.S. economy remains rooted in businesses providing essential services that continue to require human labor, local presence, and physical execution.

At Supervest, we believe these businesses deserve a place within a diversified private credit allocation.

As investors navigate one of the most significant technological shifts in modern history, understanding not only how much yield a portfolio generates—but where that yield comes from—may matter more than ever.

You may be diversified by asset class.

The more important question is whether you are diversified by economic exposure. 

As artificial intelligence reshapes the economy, that distinction may become one of the defining questions for private credit investors in the decade ahead. 

About Supervest

Supervest is an alternative investment platform providing accredited investors access to fixed-rate investment opportunities supported by diversified portfolios of revenue-based financing and receivables-backed assets serving small and medium-sized businesses throughout the United States. Since its inception, the platform has facilitated more than $250 million in investor participation across its Note offerings and institutional investment programs, attracted more than $50 million in subscriptions to its fixed-rate Note offerings, and maintained a perfect record of scheduled principal and interest payments across those Note programs.

###

Media Contact

Supervest Inc.
marketing@supervest.com
www.supervest.com

DISCLAIMER

The contents of this press release are for informational purposes only. You should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this press release constitutes a consultation or a solicitation for investment or the purchase or sale of any financial asset. Any investment decision should be made after consulting with a professional about your specific circumstances.

The information provided in this press release does not constitute advice or investment opinion, and it should not be relied upon as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any reader’s particular investment objectives, financial situations, or needs. Readers should not consider it as financial advice and should consult with their financial advisor before making any investment decisions.

Neither the distribution company nor its partners are responsible for any decision made on the basis of this press release. Any decision based on this press release should be made after consulting with a professional. The source of this press release, Supervest, must be contacted for any queries.

Attachment

• AI, Private Credit, and the Future of Cash Flow Lending

Basel, July 17, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta^® (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression¹. Fabhalta, a first-in-class complement inhibitor, received approval under a priority review designation after an initial FDA accelerated approval in August 2024 for the reduction of proteinuria in primary IgAN¹.

“IgAN is a chronic, immune-mediated disease leading to kidney failure that can have a severe impact on patients’ lives,” said Dana Rizk, M.D., Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham and APPLAUSE-IgAN Steering Committee Member. “The ability to significantly slow kidney function decline is a critical treatment goal. This approval of Fabhalta reinforces the importance of targeting underlying disease mechanisms, including complement activation, in treating IgAN to help preserve kidney health.”

Each year, approximately 25 people per million worldwide are newly diagnosed with IgAN, one of the most common autoimmune kidney diseases⁵. Up to 50 percent of IgAN patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis, often requiring dialysis and/or kidney transplantation, placing a significant burden on patients^6-10.

“This milestone is a moment of great hope for the IgAN community,” said Bonnie Schneider, Director and Co-Founder, IgA Nephropathy Foundation. “For patients and families impacted by this progressive disease, knowing that Fabhalta can help preserve kidney function brings renewed confidence and optimism for the future of the IgAN treatment landscape.”

Data supporting approval
The approval of Fabhalta was based on data from the Phase III APPLAUSE-IgAN study. Results demonstrated statistically significant and clinically meaningful improvement in estimated glomerular filtration rate (eGFR) over two years, with Fabhalta showing an annualized mean change from baseline in eGFR of -3.0 mL/min/1.73 m²/yr compared with -5.7 mL/min/1.73 m²/yr for placebo¹. Fabhalta consistently outperformed placebo across key kidney outcomes¹.

The APPLAUSE-IgAN study showed that Fabhalta has a favorable safety profile, consistent with previously reported data¹. The most common adverse events with Fabhalta in patients with IgAN were abdominal pain, dizziness and nausea¹. Fabhalta may increase the risk of serious infections caused by encapsulated bacteria and is available only through a Risk Evaluation and Mitigation Strategy (REMS) program requiring appropriate vaccinations prior to treatment¹.

Transforming care in kidney disease
“Today’s approval reinforces Fabhalta’s role in preserving kidney function by significantly slowing disease progression, an outcome that matters deeply to patients at risk of long-term kidney damage,” said Victor Bultó, President, US, Novartis. “This milestone underscores the importance of continued innovation for people living with IgAN and our commitment to addressing the underlying drivers of disease.”

As each person’s IgAN journey is unique, access to effective, targeted therapies with different mechanisms of action can help physicians select the most appropriate treatment for their patients^10-13. Alongside Fabhalta, Novartis is supporting this community through its growing IgAN portfolio, which includes Vanrafia^® (atrasentan) and investigational compound zigakibart^1,14. Novartis is committed to helping IgAN patients access Fabhalta through a variety of support programs, with nearly 100 percent of US patients paying $10 or less per month.

About Fabhalta^® (iptacopan)
Fabhalta (iptacopan) is an oral Factor B inhibitor designed to selectively target the alternative complement pathway, one of several key drivers of glomerular inflammation and kidney damage in IgAN^2-4. By inhibiting Factor B, Fabhalta aims to reduce ongoing complement-mediated injury and slow disease progression. Fabhalta has received regulatory approvals in multiple complement-mediated diseases, including IgAN, and is being evaluated across a range of rare kidney conditions.

Novartis’ commitment to kidney diseases
Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need.

Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our portfolio targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms – whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis, and get patients the right care, sooner.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

1. FABHALTA prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp; July 2026.
2. Rizk DV, Maillard N, Julian BA, et al. The emerging role of complement proteins as a target for therapy of IgA nephropathy. Front Immunol. 2019;10:504. doi:10.3389/fimmu.2019.00504
3. Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392:531–543. doi:10.1056/NEJMoa2410316
4. Chiu YL, Lin WC, Shu KH, et al. Alternative complement pathway is activated and associated with galactose-deficient IgA(1) antibody in IgA nephropathy patients. Front Immunol. 2021;12:638309. doi:10.3389/fimmu.2021.638309
5. Zhang H, Rizk DV, Perkovic V, et al. Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024;105(1):189-199. doi:10.1016/j.kint.2023.09.027
6. Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012;7(6):e38904. doi:10.1371/journal.pone.0038904
7. Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. doi:10.2215/CJN.0000000000000135
8. Hastings MC, Bursac Z, Julian BA, et al. Life expectancy for patients from the southeastern United States with IgA nephropathy. Kidney Int Rep. 2017;3(1):99-104. doi:10.1016/j.ekir.2017.08.008
9. Sim JJ et al. Poster TH-PO615 presented at: ASN Kidney Week 2023; November 2-5, 2023; Philadelphia, PA.
10. Rovin BH, Barratt J, Cook HT, et al. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025;108(4):S1-S71. doi:10.1016/j.kint.2025.04.004
11. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012;81(9):833-843.
12. Lim RS, Yeo SC, Barratt J, Rizk DV. An update on current therapeutic options in IgA nephropathy. J Clin Med. 2024;13(4):947. doi:10.3390/jcm13040947
13. Glassock RJ. An expert opinion on current and future treatment approaches in IgA nephropathy. Adv Ther. 2025;42(6):2545-2558. doi:10.1007/s12325-025-03187-7
14. ClinicalTrials.gov. A study of BION-1301 in adults with IgA nephropathy. Identifier NCT05852938. Available at: https://clinicaltrials.gov/ct2/show/NCT05852938. Accessed June 2026. 

# # #

In recent years, the market has expanded toward highly human-like interaction and emotional companionship. Chinese robotics company UBTech Robotics recently unveiled its U1 model—an ultra-biomimetic humanoid robot—marking the beginning of a new era of lifelike companion robots.

As global demographics continue to shift toward aging populations, declining birth rates, and a growing number of single-person households, demand for humanoid companion robots is being fueled by a rapidly emerging “companionship economy.” TrendForce estimates the market will reach US$1.1 billion by 2030.

TrendForce notes that Japan was among the earliest markets to develop companion robots. For instance, GROOVE X introduced LOVOT, a robot centered entirely on emotional interaction and therapeutic companionship that deliberately forgoes productivity-oriented functions. Meanwhile, Japan’s National Institute of Advanced Industrial Science and Technology (AIST) and its partners developed PARO, a seal-shaped therapeutic robot widely adopted by long-term care facilities for dementia care and psychological support.

These products have demonstrated the commercial viability of companion robots. They also illustrate Japan’s distinctive approach to companion robot design, which prioritizes cute, cartoon-like appearances to enhance user acceptance over highly realistic human forms.

Japanese designs prioritize affinity, while Chinese developers pursue human-like interaction

Compared with Japan’s emphasis on comfort and approachability, Chinese companion robots have increasingly focused on biomimetic appearances, emotional expression, and natural interactions to create a more lifelike user experience. Most manufacturers continue to prioritize companionship while introducing partially humanoid form factors.

For example, Noetix Robotics offers the desktop companion robot Xiao Yue, which features synchronized voice and facial expressions for companionship at home. Chunshuitang Health, meanwhile, focuses on highly realistic human appearances, tactile feedback, and simulated body temperature to create a more immersive companionship experience.

UBTech’s U1 takes this concept a step further. The model boasts highly realistic silicone skin, 88 degrees of freedom, and an emotion-focused LLM that can recognize multiple emotional states. The robot targets consumer applications, including family interaction and psychological support. Unlike many competitors that entered the companion robot market first and later added humanoid features, UBTech has long specialized in humanoid robotics and is now extending its products with the ability to interact emotionally.

This strategy has been enabled by the rapid advancement of China’s supply chain, AI models, and manufacturing capabilities, allowing sophisticated humanoid hardware to be combined with emotional companionship and creating new business opportunities.

TrendForce believes the launch of the U1 demonstrates that the humanoid robot supply chain is expanding beyond industrial applications into the consumer electronics market. In addition to traditional key components such as servo motors, reducers, and joint modules, the importance of high-fidelity synthetic materials, multimodal sensors, micro-expression actuators, emotion AI models, and on-device AI inference is expected to increase significantly, generating new opportunities across the robotics supply chain.

Despite strong market potential, humanoid companion robots still face several challenges. Key hurdles include battery life, the naturalness of emotional interactions, long-term personality and memory consistency, functional safety and privacy protection, and achieving the right balance between product capabilities and pricing.

Manufacturers are expected to place greater emphasis on integrating hardware, AI models, ecosystems, and content services, given that companion robots interact with users far more frequently than industrial robots. While the tens of thousands of orders reportedly received for UBTech’s U1 demonstrate encouraging initial market interest, it remains to be seen whether demand can be sustained beyond early adopters.

For more information on robot reports and market data from TrendForce, please visit the Report Page, or Email (SR_MI@trendforce.com) the Sales Department for a free sample of the 2026 market outlook.

For more on the latest technology industry news and trends, please visit News.

Media Contact

Ms. Peng Chen
pengchen@trendforce.com 

Ms. Pinchun Chou
pinchunchou@trendforce.com 

About TrendForce
TrendForce is a global leader in technology industry analysis and consulting services. With deep expertise spanning foundry, DRAM, HBM, NAND Flash, AI servers, robotics, near-eye displays, display panels, LEDs, MLCC, and green energy, it also offers in-depth research into key market drivers such as AI, automotive technologies, 5G/6G communications, LEO satellites, and the IoT.

Backed by a team of top industry professionals, TrendForce has been at the forefront of global market research for over 25 years. More than 60% of its clients are among the world’s top 500 companies. TrendForce’s global footprint includes Taipei, Shenzhen, Silicon Valley, New York, and Tokyo. With timely and strategic industry analysis, TrendForce delivers the critical information that empowers businesses to make smarter, faster decisions.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/940cbf1e-ffce-4371-8b0c-b46bdf149f8e

Japan’s Enterprises and Startups Build Industry-Specialized AI With NVIDIA Nemotron Open Models

News Summary:

• Institution of Science Tokyo, SoftBank Corp.’s SB Intuitions and Stockmark are adopting NVIDIA Nemotron to build locally developed AI models designed to serve Japanese users, businesses and institutions amid the country’s demographic and workforce transition.
• Japanese enterprises avatarin, ENEOS Holdings, Hitachi and NTT DATA are building Japanese-language AI applications with NVIDIA Nemotron, from remote-presence robotics to enterprise agents and specialized medical and contact centers.
• Sakana AI is integrating NVIDIA Nemotron into its Fugu model-routing platform, expanding the set of AI models Fugu can intelligently orchestrate to dynamically select the best model for each task.

TOKYO, July 15, 2026 (GLOBE NEWSWIRE) — NVIDIA today announced that leading Japanese enterprises, startups and research institutions are building industry-specialized AI models and applications with NVIDIA Nemotron™ open models, data and libraries, accelerating the development of AI tailored to Japan’s language, industries and workforce.

Open models are the foundation of national AI ecosystems, giving organizations the ability to customize, deploy and govern AI they control.

In Japan, these capabilities are increasingly important as the country addresses an aging population and workforce transition, driving demand for AI tailored to local industries that helps strengthen the workforce, sustain productivity and accelerate innovation.

“Every nation and every company should own and control its intelligence infrastructure. Open models make that possible,” said Jensen Huang, founder and CEO of NVIDIA. “They give countries, enterprises and researchers the freedom to inspect, improve, adapt, secure and deploy AI for their own needs. Together with Japan’s AI leaders, we are advancing an open AI ecosystem that accelerates discovery, strengthens national capability and ensures every society can participate in — and benefit from — the AI revolution.”

Building Specialized AI for Japan With NVIDIA Nemotron
Across Japan, developers are building specialized AI with NVIDIA Nemotron open models and datasets, tailoring them to the country’s industries and public-sector needs.

Institute of Science Tokyo developed its Swallow family of open foundation models using NVIDIA Nemotron datasets and the NVIDIA NeMo™ software stack for continual pretraining and post-training. Swallow models enhance Japanese language and reasoning performance while preserving the underlying models’ core English, math and coding capabilities. Enterprises are customizing and deploying Swallow for specialized use cases, including financial-document translation and asset-management report generation.

SB Intuitions Corp., SoftBank Corp.’s generative AI research subsidiary, trained its Sarashina series of homegrown generative AI models using NVIDIA Nemotron, including the NVIDIA NeMo RL and Megatron-LM libraries. Sarashina3 mini has been selected by Japan’s Digital Agency for use in specialized AI use cases. SoftBank Corp. has also developed and deployed a large telco model, using NVIDIA Nemotron, to enable autonomous telecom network operations.

Stockmark’s specialized Japanese-language document-understanding model, released today, is based on the NVIDIA Nemotron 3 Nano Omni model. The company is also developing enterprise knowledge applications using NVIDIA NeMo Retriever™ and the Nemotron-Personas-Japan dataset, serving customers across Japan’s manufacturing, energy and chemical industries through Japan’s Generative AI Accelerator Challenge national project.

Transforming Japan’s Industries With NVIDIA Nemotron
Japanese enterprises are using NVIDIA Nemotron to modernize essential services, improve productivity and support the country’s workforce.

AI and robotics startup avatarin is using NVIDIA Nemotron open models and NVIDIA NeMo to develop Japanese-language speech and reasoning capabilities for enterprise AI agents. NVIDIA HGX™ B300 systems provide the private AI infrastructure that enables those agents to securely analyze customer conversations and access enterprise knowledge for more accurate responses, while NVIDIA Jetson™ powers edge AI capabilities, including digital avatar systems being deployed at airports and other locations across Japan.

ENEOS Holdings is using NVIDIA Nemotron open models with the NVIDIA AI-Q Blueprint and NVIDIA ALCHEMI NIM microservices to advance agentic AI workflows for energy and materials R&D. Researchers are using these technologies to integrate technical document search, vision and language understanding, and simulation-backed molecular screening, helping accelerate materials exploration for applications such as immersion-cooling fluids and advanced catalysts.

NTT DATA, an operating subsidiary of NTT, used NVIDIA Nemotron-Personas-Japan to augment training data for its proprietary tsuzumi 2 model, improving question-answering accuracy and enhancing responses to questions requiring additional knowledge. The company is also looking to deploy a scalable multi-agent framework harnessing NVIDIA Agent Toolkit, including NVIDIA Nemotron, to route tasks to the best models and drive accurate, efficient and autonomous enterprise workflows.

Hitachi is developing physical AI technologies to address real-world operational challenges by using NVIDIA Nemotron and NVIDIA Cosmos™ open models, along with its proprietary information technology (IT) and operational technology (OT) domain knowledge. As part of a multi-agent orchestration platform, these technologies are designed to connect and coordinate IT and OT operations, helping transform enterprise-scale business processes across complex workflows.

Sakana AI is collaborating with NVIDIA to integrate NVIDIA Nemotron into its Fugu model-orchestration platform, expanding the range of AI models Fugu can intelligently orchestrate to dynamically select the best model for each task in agentic AI workflows. By routing each request to the model best suited for the job, Fugu helps developers balance accuracy, performance and cost across multiple open and proprietary AI models. Fugu demonstrates how thoughtful orchestration can unlock capabilities beyond what an individual model achieves on its own. Early performance results on complex, real-world coding tasks reinforce the promise of coordination as a path to more capable AI.

Open and Customizable, Deployable Anywhere
Nemotron models are released with open weights, datasets and recipes, giving organizations the transparency and control to customize models for domain-specific workflows and deploy them where their applications and data reside.

Developers can use NVIDIA NeMo to customize, evaluate and optimize models for their use cases, and deploy them in environments that meet regulatory, sovereignty and data localization requirements.

Nemotron models are available on Hugging Face, ModelScope, OpenRouter and build.nvidia.com as NVIDIA NIM™ microservices, and through NVIDIA Cloud Partners, inference platforms and cloud service providers.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:
Natalie Hereth
Corporate Communications
NVIDIA Corporation
press@nvidia.com

Certain statements in this press release including, but not limited to, statements as to: Together with Japan’s AI leaders, NVIDIA advancing an open AI ecosystem that accelerates discovery, strengthens national capability and ensures every society can participate in — and benefit from — the AI revolution; expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, Nemotron, NVIDIA Cosmos, NVIDIA HGX, NVIDIA Jetson, NVIDIA NeMo and NVIDIA NeMo Retriever are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/11dc96e1-0143-4627-8503-c33b1345d070